Buchumschlag

Does comorbid disruptive behavior modify the effects of atomoxetine on ADHD symptoms as measured by a continuous performance test and a motion tracking device?

Objective: To compare the reduction of ADHD symptoms under atomoxetine in patients with and without comorbid oppositional defiant disorder (ODD) or conduct disorder (CD) using a computer-based continuous performance test (cb-CPT) combined with an infrared motion tracking (MT) device. Method: Seconda...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Wehmeier, Peter M. (VerfasserIn) , Banaschewski, Tobias (VerfasserIn) , Dittmann, Ralf (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 2015
In: Journal of attention disorders
Year: 2015, Jahrgang: 19, Heft: 7, Pages: 591-602
ISSN:1557-1246
DOI:10.1177/1087054712456739
Online-Zugang:Verlag, Volltext: http://dx.doi.org/10.1177/1087054712456739
Verlag, Volltext: https://doi.org/10.1177/1087054712456739
Volltext
Verfasserangaben:Peter M. Wehmeier, Laura Kipp, Tobias Banaschewski, Ralf W. Dittmann, and Alexander Schacht
Beschreibung
Zusammenfassung:Objective: To compare the reduction of ADHD symptoms under atomoxetine in patients with and without comorbid oppositional defiant disorder (ODD) or conduct disorder (CD) using a computer-based continuous performance test (cb-CPT) combined with an infrared motion tracking (MT) device. Method: Secondary analysis of a placebo-controlled study in ADHD patients (6-12 years old) treated with atomoxetine (target dose: 1.2 mg/kg per day). Cb-CPT/MT scores were analyzed using ANCOVA (last observation carried forward [LOCF]). Results: The data (N = 125) suggested a more pronounced atomoxetine effect in the group with comorbid ODD/CD as measured by all cb-CPT/MT parameters except for “normalized variation of reaction time” (nVRT). Conclusion: The results showed that atomoxetine reduced ADHD severity as measured by cb-CPT and MT parameters regardless of whether comorbid ODD/CD was present. The treatment effect of atomoxetine on hyperactivity appears to be more pronounced in the subgroup of patients with comorbid ODD/CD than in the subgroup without this comorbidity.
Beschreibung:Gesehen am 15.03.2018
Beschreibung:Online Resource
ISSN:1557-1246
DOI:10.1177/1087054712456739

Ähnliche Einträge